Cancer Network Staff

Explore 5 essential takeaways for oncology clinicians regarding the use of GLP-1 receptor agonists in breast cancer management.

Cadonilimab monotherapy did not yet reach the median OS or PFS at the time of data cutoff for these patients with recurrent or metastatic cervical cancer.

Namodenoson did not exhibit any new safety signals or unexpected toxicity as a treatment for patients with PDAC who progressed on at least 1 systemic therapy.

In the phase 3 neoCARHP trial, THP showed noninferior pathologic complete response rates compared with TCbHP in patients with HER2-positive breast cancer.

A White Paper showed there was no convincing evidence that GLP-1 RAs cause papillary, follicular, or Oncocytic thyroid cancers.

The FDA tentatively approved PNT2003, a radioequivalent to lutetium Lu 177 dotatate, for adults with GEP-NETs based on comparable efficacy and safety data.

Relacorilant plus nab-paclitaxel improved PFS among patients with PROC who had progression after a PARP inhibitor or who were 65 years or older.

Explore the latest clinical data and therapeutic strategies for acral, mucosal, and uveal melanomas from Mark B. Faries, MD, FACS.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

A partial clinical hold has been placed on the phase 2 LINNET trial following the report of several serious safety events, including 1 treatment-related death.

James Larkin, MD, PhD, highlighted toxicities associated with immune checkpoint inhibitors in melanoma at a recent Physicians Education Resource meeting.

SRN-101, an AAV-based immuno-gene therapy, has received fast track designation for the treatment of recurrent high-grade glioma.

First-line nivolumab plus chemotherapy provides a durable survival benefit in advanced gastric cancers, particularly in patients with a PD-L1 CPS of 5 or higher.

Omid Hamid, MD, presented at the 22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies on the evolving landscape of perioperative immunotherapy and targeted therapy.

Pembrolizumab/lenvatinib yielded a 40% ORR in patients with recurrent gynecologic clear cell carcinoma, including those with prior anti-angiogenic therapy.

The FDA has cleared an IND application for FG001, allowing the developer to initiate its first US registration trial in patients with high-grade glioma.

A phase 1 trial evaluating PLT012 in HCC, among other solid tumors, is currently underway and will report safety and preliminary clinical activity data.

Charlotte Ivey Rivers, MD, discussed the importance of rare CNS tumor research, upcoming trial data in meningioma, and the role of functional radiosurgery.

Neoadjuvant mFOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma demonstrated a 100% R0 resection rate.

Phase 2 CRDF-004 findings show that adding onvansertib to FOLFIRI and bevacizumab improves PFS in first-line RAS-mutated metastatic colorectal cancer.

Patient characteristics such as female sex and receipt of pylorus-preserving gastrectomy were protective of gallstone disease risk in those who had gastric cancer.

Encorafenib, cetuximab, and FOLFIRI improved PFS vs in treatment-naive BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER trial.

Neoadjuvant therapy improves survival for patients with upfront resectable pancreatic cancer and minor PMV abutment vs an upfront surgical approach.

The PRECEDE Consortium is a multidisciplinary effort to drive the earlier detection of pancreatic cancer and raise the survival rate to 50%.

HCB101 in combination with HER2-targeted therapy or ramucirumab plus paclitaxel achieved positive responses among patients with first- and second-line gastric cancer.

PANOVA-3 findings demonstrated that patients with previously untreated pancreatic cancer experienced better outcomes when adding TTFields to chemotherapy.

Surgical updates for invasive breast cancer from the NCCN Breast Cancer meeting revealed insights on neoadjuvant endocrine therapy and SLNB omission.

Nivolumab improved 9-year recurrence-free survival compared with ipilimumab for resected stage III or IV melanoma in the phase 3 CheckMate 238 trial.

Irpagratinib demonstrated superior survival among patients with hepatocellular carcinoma who were pretreated with ICIs and mTKIs.

Supporting results for zenocutuzumab in patients with NRG1 fusion–positive CCA come from the phase 1/2 eNRGy trial.